{
    "class": "Abstract",
    "records": {
        "2011 ASCO Annual Meeting Abstract#10006": {
            "abstractNumber": "10006",
            "displayName": "ASCO 2011 (abstract 10006)",
            "meeting": "2011 ASCO Annual Meeting",
            "name": "A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).",
            "url": "https://meetinglibrary.asco.org/record/62790",
            "year": "2011"
        },
        "2011 ASCO Annual Meeting Abstract#10009": {
            "abstractNumber": "10009",
            "displayName": "ASCO 2011 (abstract 10009)",
            "meeting": "2011 ASCO Annual Meeting",
            "name": "Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.",
            "url": "https://meetinglibrary.asco.org/record/63320",
            "year": "2011"
        },
        "2011 ASCO Annual Meeting Abstract#8061": {
            "abstractNumber": "8061",
            "displayName": "ASCO 2011 (abstract 8061)",
            "meeting": "2011 ASCO Annual Meeting",
            "name": "Cell cycle effects of CDK 4/6 inhibitor PD 0332991 in diffuse large B-cell lymphoma cell lines in vitro.",
            "url": "https://meetinglibrary.asco.org/record/61678/abstract",
            "year": "2011"
        },
        "2013 ASCO Annual Meeting Abstract#2500": {
            "abstractNumber": "2500",
            "displayName": "ASCO 2013 (abstract 2500)",
            "meeting": "2013 ASCO Annual Meeting",
            "name": "A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.",
            "url": "https://meetinglibrary.asco.org/record/82444/abstract",
            "year": "2013"
        },
        "2013 ASCO Annual Meeting Abstract#2531": {
            "abstractNumber": "2531",
            "displayName": "ASCO 2013 (abstract 2531)",
            "doi": "10.1200/jco.2013.31.15_suppl.2531",
            "meeting": "2013 ASCO Annual Meeting",
            "name": "Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study.",
            "url": "https://meetinglibrary.asco.org/record/82722/abstract",
            "year": "2013"
        },
        "2013 ASCO Annual Meeting Abstract#2532": {
            "abstractNumber": "2532",
            "displayName": "ASCO 2013 (abstract 2532)",
            "meeting": "2013 ASCO Annual Meeting",
            "name": "A pilot study of sirolimus (S) in subjects with Cowden syndrome (CS) with germ-line mutations in PTEN.",
            "url": "https://meetinglibrary.asco.org/record/85566",
            "year": "2013"
        },
        "2013 ASCO Annual Meeting Abstract#2605": {
            "abstractNumber": "2605",
            "displayName": "ASCO 2013 (abstract 2605)",
            "meeting": "2013 ASCO Annual Meeting",
            "name": "Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer.",
            "url": "https://meetinglibrary.asco.org/record/82827",
            "year": "2013"
        },
        "2013 ASCO Annual Meeting Abstract#8023": {
            "abstractNumber": "8023",
            "displayName": "ASCO 2013 (abstract 8023)",
            "meeting": "2013 ASCO Annual Meeting",
            "name": "NTRK1 gene fusions as a novel oncogene target in lung cancer.",
            "url": "https://meetinglibrary.asco.org/record/82496",
            "year": "2013"
        },
        "2013 ASCO Annual Meeting Abstract#9029": {
            "abstractNumber": "9029",
            "displayName": "ASCO 2013 (abstract 9029)",
            "meeting": "2013 ASCO Annual Meeting",
            "name": "Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.",
            "url": "https://meetinglibrary.asco.org/record/80857",
            "year": "2013"
        },
        "2013 ASCO Annual Meeting Abstract#CRA9003": {
            "abstractNumber": "CRA9003",
            "displayName": "ASCO 2013 (abstract CRA9003)",
            "meeting": "2013 ASCO Annual Meeting",
            "name": "Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).",
            "url": "https://meetinglibrary.asco.org/record/80820",
            "year": "2013"
        },
        "2014 ASCO Annual Meeting Abstract#10018": {
            "abstractNumber": "10018",
            "displayName": "ASCO 2014 (abstract 10018)",
            "meeting": "2014 ASCO Annual Meeting",
            "name": "Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).",
            "url": "https://meetinglibrary.asco.org/record/92029",
            "year": "2014"
        },
        "2014 ASCO Annual Meeting Abstract#2514": {
            "abstractNumber": "2514",
            "displayName": "ASCO 2014 (abstract 2514)",
            "meeting": "2014 ASCO Annual Meeting",
            "name": "A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.",
            "url": "https://meetinglibrary.asco.org/record/94866",
            "year": "2014"
        },
        "2014 ASCO Annual Meeting Abstract#2528": {
            "abstractNumber": "2528",
            "displayName": "ASCO 2014 (abstract 2528)",
            "meeting": "2014 ASCO Annual Meeting",
            "name": "A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.",
            "url": "https://meetinglibrary.asco.org/record/94422",
            "year": "2014"
        },
        "2014 ASCO Annual Meeting Abstract#3515": {
            "abstractNumber": "3515",
            "displayName": "ASCO 2014 (abstract 3515)",
            "meeting": "2014 ASCO Annual Meeting",
            "name": "Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).",
            "url": "https://meetinglibrary.asco.org/record/94751",
            "year": "2014"
        },
        "2014 ASCO Annual Meeting Abstract#5513": {
            "abstractNumber": "5513",
            "displayName": "ASCO 2014 (abstract 5513)",
            "doi": "10.1200/jco.2014.32.15_suppl.5513",
            "meeting": "2014 ASCO Annual Meeting",
            "name": "Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.",
            "url": "https://meetinglibrary.asco.org/record/92899/abstract",
            "year": "2014"
        },
        "2014 ASCO Annual Meeting Abstract#8001": {
            "abstractNumber": "8001",
            "displayName": "ASCO 2014 (abstract 8001)",
            "meeting": "2014 ASCO Annual Meeting",
            "name": "Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).",
            "url": "https://meetinglibrary.asco.org/record/92507",
            "year": "2014"
        },
        "2014 ASCO Annual Meeting Abstract#8009": {
            "abstractNumber": "8009",
            "displayName": "ASCO 2014 (abstract 8009)",
            "meeting": "2014 ASCO Annual Meeting",
            "name": "Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).",
            "url": "https://meetinglibrary.asco.org/record/92346",
            "year": "2014"
        },
        "2014 ASCO Annual Meeting Abstract#8015": {
            "abstractNumber": "8015",
            "displayName": "ASCO 2014 (abstract 8015)",
            "meeting": "2014 ASCO Annual Meeting",
            "name": "Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).",
            "url": "https://meetinglibrary.asco.org/record/92532",
            "year": "2014"
        },
        "2015 ASCO Annual Meeting Abstract#1003": {
            "abstractNumber": "1003",
            "displayName": "ASCO 2015 (abstract 1003)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).",
            "url": "https://meetinglibrary.asco.org/record/109828",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#103": {
            "abstractNumber": "103",
            "displayName": "ASCO 2015 (abstract 103)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Phase 1/2 Study of the MEK Inhibitor Trametinib, BRAF Inhibitor Dabrafenib, and Anti-EGFR Antibody Panitumumab in Patients With BRAF V600E-Mutated Metastatic Colorectal Cancer",
            "url": "https://meetinglibrary.asco.org/record/109909/abstract",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#10517": {
            "abstractNumber": "10517",
            "displayName": "ASCO 2015 (abstract 10517)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Detection of KIT mutants in circulating tumor DNA (ctDNA) and their association with ponatinib anti-tumor activity in patients (pts) with advanced gastrointestinal stromal tumors (GIST).",
            "url": "https://meetinglibrary.asco.org/record/112012",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#10564": {
            "abstractNumber": "10564",
            "displayName": "ASCO 2015 (abstract 10564)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.",
            "url": "https://meetinglibrary.asco.org/record/115553/abstract",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#11010": {
            "abstractNumber": "11010",
            "displayName": "ASCO 2015 (abstract 11010)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.",
            "url": "https://meetinglibrary.asco.org/record/111857",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#11075": {
            "abstractNumber": "11075",
            "displayName": "ASCO 2015 (abstract 11075)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.",
            "url": "https://meetinglibrary.asco.org/record/111332",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#11091": {
            "abstractNumber": "11091",
            "displayName": "ASCO 2015 (abstract 11091)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Investigation of non-V600 BRAF mutations commonly found in NSCLC for their sensitivity to dabrafenib or trametinib.",
            "url": "https://meetinglibrary.asco.org/record/111274",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#2500": {
            "abstractNumber": "2500",
            "displayName": "ASCO 2015 (abstract 2500)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "A Pharmacokinetically and Pharmacodynamically Driven Phase I Trial of the Pan-AKT Inhibitor AZD5363 with Expansion Cohorts in PIK3CA Mutant Breast and Gynecological Cancers",
            "url": "https://meetinglibrary.asco.org/record/109086",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#2501": {
            "abstractNumber": "2501",
            "displayName": "ASCO 2015 (abstract 2501)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "First-in-Human, Phase I, Dose-Escalation Study of Selective PI3Ka Isoform Inhibitor MLN1117 in Patients with Advanced Solid Malignancies",
            "url": "https://meetinglibrary.asco.org/record/109089",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#2508": {
            "abstractNumber": "2508",
            "displayName": "ASCO 2015 (abstract 2508)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Phase II Multicenter Proof of Concept Study of AZD4547 in FGFR Amplified Tumours",
            "url": "https://meetinglibrary.asco.org/record/109100",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#2516": {
            "abstractNumber": "2516",
            "displayName": "ASCO 2015 (abstract 2516)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.",
            "url": "https://meetinglibrary.asco.org/record/112038",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#2595": {
            "abstractNumber": "2595",
            "displayName": "ASCO 2015 (abstract 2595)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Activity of crizotinib in relapsed MET amplified malignancies: Results of the French AcSé Program.",
            "url": "https://meetinglibrary.asco.org/record/109388/abstract",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#3508": {
            "abstractNumber": "3508",
            "displayName": "ASCO 2015 (abstract 3508)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.",
            "url": "https://meetinglibrary.asco.org/record/112091",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#4119": {
            "abstractNumber": "4119",
            "displayName": "ASCO 2015 (abstract 4119)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer.",
            "url": "https://meetinglibrary.asco.org/record/108962",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#4519": {
            "abstractNumber": "4519",
            "displayName": "ASCO 2015 (abstract 4519)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Activating genomic mutations in the mTOR pathway predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.",
            "url": "https://meetinglibrary.asco.org/record/109739/abstract",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#5508": {
            "abstractNumber": "5508",
            "displayName": "ASCO 2015 (abstract 5508)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.",
            "url": "https://meetinglibrary.asco.org/record/109476",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#8006": {
            "abstractNumber": "8006",
            "displayName": "ASCO 2015 (abstract 8006)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).",
            "url": "https://meetinglibrary.asco.org/record/116755/abstract",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#8089": {
            "abstractNumber": "8089",
            "displayName": "ASCO 2015 (abstract 8089)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Response to tyrosine kinase inhibtors in non-small-cell lung cancer with concomitant c-MET overexpression and driver genes.",
            "url": "https://meetinglibrary.asco.org/record/109612/abstract",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#e15516": {
            "abstractNumber": "e15516",
            "displayName": "ASCO 2015 (abstract e15516)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "Association of HER2 and ErbB3 molecular alterations with afatinib sensitivity in platinum-refractory metastatic urothelial carcinoma (UC) in a phase II trial.",
            "url": "https://meetinglibrary.asco.org/record/110379",
            "year": "2015"
        },
        "2015 ASCO Annual Meeting Abstract#e19028": {
            "abstractNumber": "e19028",
            "displayName": "ASCO 2015 (abstract e19028)",
            "meeting": "2015 ASCO Annual Meeting",
            "name": "A Phase II study to evaluate the efficacy of erlotinib in advanced NSCLC patients who have wild-type EGFR and EGFR gene amplification.",
            "url": "https://meetinglibrary.asco.org/record/114718",
            "year": "2015"
        },
        "2016 ASCO Annual Meeting Abstract#10555": {
            "abstractNumber": "10555",
            "displayName": "ASCO 2016 (abstract 10555)",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "Dose-finding study of vinblastine in combination with nilotinib in children, adolescents and young adults with refractory or recurrent low-grade glioma: Results of the ITCC/SIOPE-Brain VINILO phase I trial (NCT01887522).",
            "url": "https://meetinglibrary.asco.org/record/123089",
            "year": "2016"
        },
        "2016 ASCO Annual Meeting Abstract#109": {
            "abstractNumber": "109",
            "displayName": "ASCO 2016 (abstract 109)",
            "doi": "10.1200/JCO.2016.34.15_suppl.109",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy.",
            "url": "https://meetinglibrary.asco.org/record/126707/abstract",
            "year": "2016"
        },
        "2016 ASCO Annual Meeting Abstract#11010": {
            "abstractNumber": "11010",
            "displayName": "ASCO 2016 (abstract 11010)",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations.",
            "url": "https://meetinglibrary.asco.org/record/123163",
            "year": "2016"
        },
        "2016 ASCO Annual Meeting Abstract#11053": {
            "abstractNumber": "11053",
            "displayName": "ASCO 2016 (abstract 11053)",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).",
            "url": "https://meetinglibrary.asco.org/record/123172",
            "year": "2016"
        },
        "2016 ASCO Annual Meeting Abstract#2019": {
            "abstractNumber": "2019",
            "displayName": "ASCO 2016 (abstract 2019)",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.",
            "url": "https://meetinglibrary.asco.org/record/125346",
            "year": "2016"
        },
        "2016 ASCO Annual Meeting Abstract#2558": {
            "abstractNumber": "2558",
            "displayName": "ASCO 2016 (abstract 2558)",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.",
            "url": "https://meetinglibrary.asco.org/record/125729",
            "year": "2016"
        },
        "2016 ASCO Annual Meeting Abstract#2581": {
            "abstractNumber": "2581",
            "displayName": "ASCO 2016 (abstract 2581)",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.",
            "url": "https://meetinglibrary.asco.org/record/125736",
            "year": "2016"
        },
        "2016 ASCO Annual Meeting Abstract#520": {
            "abstractNumber": "520",
            "displayName": "ASCO 2016 (abstract 520)",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).",
            "url": "https://meetinglibrary.asco.org/record/124326",
            "year": "2016"
        },
        "2016 ASCO Annual Meeting Abstract#9067": {
            "abstractNumber": "9067",
            "displayName": "ASCO 2016 (abstract 9067)",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).",
            "url": "https://meetinglibrary.asco.org/record/123470",
            "year": "2016"
        },
        "2016 ASCO Annual Meeting Abstract#e17557": {
            "abstractNumber": "e17557",
            "displayName": "ASCO 2016 (abstract e17557)",
            "meeting": "2016 ASCO Annual Meeting",
            "name": "Hormone and targeted therapies in metastatic salivary duct carcinoma.",
            "url": "https://meetinglibrary.asco.org/record/128468/abstract",
            "year": "2016"
        },
        "2017 ASCO Annual Meeting Abstract#2500": {
            "abstractNumber": "2500",
            "displayName": "ASCO 2017 (abstract 2500)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.",
            "url": "https://meetinglibrary.asco.org/record/144575",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#2508": {
            "abstractNumber": "2508",
            "displayName": "ASCO 2017 (abstract 2508)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.",
            "url": "https://meetinglibrary.asco.org/record/144577",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#2572": {
            "abstractNumber": "2572",
            "displayName": "ASCO 2017 (abstract 2572)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.",
            "url": "https://meetinglibrary.asco.org/record/149359",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#8510": {
            "abstractNumber": "8510",
            "displayName": "ASCO 2017 (abstract 8510)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial.",
            "url": "https://meetinglibrary.asco.org/record/145463",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#9054": {
            "abstractNumber": "9054",
            "displayName": "ASCO 2017 (abstract 9054)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.",
            "url": "https://meetinglibrary.asco.org/record/152443",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#9056": {
            "abstractNumber": "9056",
            "displayName": "ASCO 2017 (abstract 9056)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.",
            "url": "https://meetinglibrary.asco.org/record/145758",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#9062": {
            "abstractNumber": "9062",
            "displayName": "ASCO 2017 (abstract 9062)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "Response of germline and somatic smoothened (SMO) mutations in non-small cell lung cancer (NSCLC) to hedgehog inhibitor vismodegib.",
            "url": "https://meetinglibrary.asco.org/record/152621",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#9065": {
            "abstractNumber": "9065",
            "displayName": "ASCO 2017 (abstract 9065)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.",
            "url": "https://meetinglibrary.asco.org/record/145774",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#9072": {
            "abstractNumber": "9072",
            "displayName": "ASCO 2017 (abstract 9072)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies.",
            "url": "https://meetinglibrary.asco.org/record/145735",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#9519": {
            "abstractNumber": "9519",
            "displayName": "ASCO 2017 (abstract 9519)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).",
            "url": "https://meetinglibrary.asco.org/record/147511",
            "year": "2017"
        },
        "2017 ASCO Annual Meeting Abstract#e23150": {
            "abstractNumber": "e23150",
            "displayName": "ASCO 2017 (abstract e23150)",
            "meeting": "2017 ASCO Annual Meeting",
            "name": "In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict clinical response to HER2 targeted therapies.",
            "url": "https://meetinglibrary.asco.org/record/146441",
            "year": "2017"
        },
        "2018 ASCO Annual Meeting Abstract#102": {
            "abstractNumber": "102",
            "displayName": "ASCO 2018 (abstract 102)",
            "meeting": "2018 ASCO Annual Meeting",
            "name": "A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.",
            "url": "https://meetinglibrary.asco.org/record/161573",
            "year": "2018"
        },
        "2018 ASCO Annual Meeting Abstract#4503": {
            "abstractNumber": "4503",
            "displayName": "ASCO 2018 (abstract 4503)",
            "meeting": "2018 ASCO Annual Meeting",
            "name": "First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).",
            "url": "https://meetinglibrary.asco.org/record/160559",
            "year": "2018"
        },
        "2018 ASCO Annual Meeting Abstract#TPS7081": {
            "abstractNumber": "TPS7081",
            "displayName": "ASCO 2018 (abstract TPS7081)",
            "meeting": "2018 ASCO Annual Meeting",
            "name": "Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.",
            "url": "https://meetinglibrary.asco.org/record/165501",
            "year": "2018"
        }
    },
    "sources": {
        "default": {
            "displayName": "ASCO",
            "longName": "American Society of Clinical Oncology",
            "name": "asco",
            "url": "https://meetinglibrary.asco.org"
        }
    }
}
